NCT01107236

Brief Summary

The purpose of this study is to assess the safety of IW-6118 when administered as a single oral dose to patients undergoing third molar extraction. Efficacy will be assessed in an exploratory manner.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for phase_2 healthy

Timeline
Completed

Started Jun 2010

Shorter than P25 for phase_2 healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 19, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 20, 2010

Completed
1 month until next milestone

Study Start

First participant enrolled

June 1, 2010

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2010

Completed
Last Updated

August 11, 2022

Status Verified

August 1, 2022

Enrollment Period

2 months

First QC Date

April 19, 2010

Last Update Submit

August 9, 2022

Conditions

Keywords

Healthy subjects

Outcome Measures

Primary Outcomes (1)

  • Safety Assessments

    Adverse events, vital signs, laboratory parameters, and ECGs will be assessed.

    Duration of the Study

Study Arms (3)

IW-6118

EXPERIMENTAL
Drug: IW-6118

Placebo

PLACEBO COMPARATOR
Drug: Matching Placebo

Naproxen Sodium

ACTIVE COMPARATOR
Drug: Naproxen Sodium

Interventions

Single dose

IW-6118

Single dose of matching placebo for IW-6118 and/or matching placebo for naproxen sodium

Placebo

Single dose

Naproxen Sodium

Eligibility Criteria

Age18 Years - 30 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Between 18 and 30 years old at time of screening;
  • BMI \> 18.5 and \< 30.0;
  • In overall good health with no clinically-significant laboratory, ECG, or physical exam findings;
  • Patient requires two ipsilateral third molar extractions of which one must be a full or partial bony mandibular impaction;
  • Women of childbearing potential must have a negative pregnancy test and must agree to use double-barrier contraception;

You may not qualify if:

  • History of any clinically-significant medical condition;
  • Previous usage of prescription, OTC, or investigational drugs as per protocol requirements;
  • Inadequate levels of pain to be included in the study;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ironwood Investigational Site

Salt Lake City, Utah, 84124, United States

Location

MeSH Terms

Interventions

Naproxen

Intervention Hierarchy (Ancestors)

Naphthaleneacetic AcidsNaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPolycyclic Compounds

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 19, 2010

First Posted

April 20, 2010

Study Start

June 1, 2010

Primary Completion

August 1, 2010

Study Completion

August 1, 2010

Last Updated

August 11, 2022

Record last verified: 2022-08

Locations